CRO support for ncats regulatory affairs support and related services
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95022D00013
- Awardee
-
CCS Associates, Inc. UEI VCNRS52G5PG7
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 4 $741,425 obligated
Award facts
- Opportunity
-
- CRO Support for NCATS Regulatory Affairs Support and Related Services Pre-Solicitation · 75N95021R00008 · Posted Dec 14, 2020
- Combined order value
-
- $741,425 Current, with exercised options
- $1,061,004 Potential, with all options
- Last date to order 88% complete
- IDV ceiling 4% used
- $19,364,880.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute on Drug Abuse awarded a multiple-award IDIQ to CCS Associates, Inc., a woman-owned small business, on June 10, 2022, with a ceiling value of $19,364,880 under the Total Small Business set-aside for CRO support and regulatory affairs support and related services. The contract extends through June 9, 2027.
Place of performance is San Jose, California. The originating solicitation, posted December 14, 2020, sought regulatory affairs, scientific consulting, and biomedical research support services.
Recent delivery-order activity under this IDIQ includes a September 1, 2026 order from the National Center for Advancing Translational Sciences valued at $159,115.55 for regulatory support for lead gene therapy candidates treating congenital myasthenic syndromes, running through August 31, 2029. A May 21, 2025 order from NCATS, valued at $545,690.33 on a labor-hours basis, supported regulatory activities for PCCA and MMAB gene therapy products through May 20, 2028. The National Institute on Drug Abuse issued a September 22, 2022 delivery order valued at $115,300.73 for pre-IND application preparation and filing support for mitragynine clinical development, completed September 21, 2025. An earlier June 10, 2022 order from NIDA, valued at $240,897.48, supported IND application preparation for Jansen's Metaphyseal Chondrodysplasia treatment. CCS Associates self-performs all labor under these engagements.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95022D00013?
75N95022D00013 was awarded to CCS Associates, Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 10, 2022.
How much is contract 75N95022D00013 worth?
Orders under 75N95022D00013 have obligated $741,425. Their combined potential value, with all options, is $1,061,004. 75N95022D00013's own ceiling is $19,364,880.
How many orders have been placed under contract 75N95022D00013?
4 orders have been placed under 75N95022D00013, the latest on September 1, 2026.
Who can order from contract 75N95022D00013?
75N95022D00013 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95022D00013 competed?
The extent of competition for 75N95022D00013 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV